Related Experiment Video

Updated: Apr 29, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

2.1K

Neutropenia after the third cycle of etanercept: could it be due to immunogenicity?

Nancy J Olsen1, Nada Elmagboul

  • 1Department of Medicine Penn State MS Hershey Medical Center Hershey, PA nolsen@hmc.psu.edu.

Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|May 23, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.2K
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.5K

Related Experiment Videos

Last Updated: Apr 29, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

2.1K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.2K
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.5K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

93
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93

Articles linked to this work by shared authors, journal, and citation graph.

A prospective study of eating disorders and risk of rheumatoid arthritis.

Seminars in arthritis and rheumatism·2025

A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease.

Lupus science & medicine·2025

IRF7 controls spontaneous autoimmune germinal center and plasma cell checkpoints.

The Journal of experimental medicine·2025

IRF7 controls spontaneous autoimmune germinal center and plasma cell checkpoints.

bioRxiv : the preprint server for biology·2025

Integrating electronic health records and GWAS summary statistics to predict the progression of autoimmune diseases from preclinical stages.

Nature communications·2025

Knowledge, Attitudes, and Intention Toward HPV Vaccination Among Reproductive-aged Women With Rheumatic Diseases.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026

Recommendations of the Argentine Society of Rheumatology for the Treatment of Patients With Rheumatoid Arthritis. Update 2025 Part II. Definitions in the Context of RA Treatment and Therapeutic Strategies for Special Situations and Comorbidities.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026

Reported Clinical Practice in Still Disease in France in 2024: A Descriptive Analysis and Comparison With Current Different National Guidelines.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026

Systemic Sclerosis-associated Interstitial Lung Disease at 2 Tertiary Centers in the USA and Greece: A Comparative Study of Demographics, Management, and Radiologic Progression.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026

Sociodemographic Characteristics of Speakers at PANLAR Congresses: Is There a Homogeneous Sex Distribution?

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026

Clinical Presentation and Longitudinal Outcomes of Individuals With Down Syndrome-Associated Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) Registry.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026

T cells in systemic lupus erythematosus: biology and clinical value.

Arthritis & rheumatology (Hoboken, N.J.)·2026

P2X7R+CD8αβ+ T cells exacerbate postoperative ileus by inducing the loss of enterochromaffin cells.

iScience·2026

Incremental prognostic value of pan-immune-inflammation value in conservatively treated acute myocardial infarction: derivation and MIMIC-IV validation.

Frontiers in cardiovascular medicine·2026

Hierarchical prompting with reasoning large language models for immune checkpoint inhibitor-associated myocarditis evidence extraction pilot study.

European heart journal. Digital health·2026

Comparative Diagnostic Yield of Rapid Immunoassay-Based Tests and Nucleic Acid Testing for Transfusion-Transmissible Infections in a Tertiary Care Setting.

Cureus·2026

Atezolizumab-bevacizumab rechallenge after immune checkpoint inhibitor-associated myocarditis in advanced hepatocellular carcinoma: a case report.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us